NO320054B1 - Oral farmasoytisk sammensetning med en forbindelse som har antisopp aktivitet og en metode for dens fremstilling - Google Patents

Oral farmasoytisk sammensetning med en forbindelse som har antisopp aktivitet og en metode for dens fremstilling Download PDF

Info

Publication number: NO320054B1
Authority: NO; Norway
Prior art keywords: pharmaceutical composition; oral pharmaceutical; compound; hydrophilic polymer; inert core
Prior art date: 1998-07-21

Application number

NO20010289A

Other languages

English (en)

Norwegian (no)

Other versions

NO20010289D0 (no

NO20010289L (no

Inventor

Carlos Picarnell Darder

Original Assignee

Liconsa Liberacion Controlada

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-21

Filing date

2001-01-17

Publication date

2005-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8304581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO320054(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-17 Application filed by Liconsa Liberacion Controlada filed Critical Liconsa Liberacion Controlada

2001-01-17 Publication of NO20010289D0 publication Critical patent/NO20010289D0/no

2001-03-07 Publication of NO20010289L publication Critical patent/NO20010289L/no

2005-10-17 Publication of NO320054B1 publication Critical patent/NO320054B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 21
150000001875 compounds Chemical class 0.000 title claims abstract description 17
230000000843 anti-fungal effect Effects 0.000 title claims description 15
239000008203 oral pharmaceutical composition Substances 0.000 title claims description 12
238000002360 preparation method Methods 0.000 title description 3
238000000576 coating method Methods 0.000 claims abstract description 22
239000011248 coating agent Substances 0.000 claims abstract description 18
229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 14
238000001035 drying Methods 0.000 claims abstract description 13
239000002736 nonionic surfactant Substances 0.000 claims abstract description 9
230000008569 process Effects 0.000 claims abstract description 9
239000002245 particle Substances 0.000 claims abstract description 4
239000003795 chemical substances by application Substances 0.000 claims abstract 2
229940121375 antifungal agent Drugs 0.000 claims description 10
239000008188 pellet Substances 0.000 claims description 9
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
238000005507 spraying Methods 0.000 claims description 6
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 5
229960004130 itraconazole Drugs 0.000 claims description 5
239000002356 single layer Substances 0.000 claims description 5
HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 claims description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
239000005720 sucrose Substances 0.000 claims description 4
239000004094 surface-active agent Substances 0.000 claims description 4
229950005137 saperconazole Drugs 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
150000005215 alkyl ethers Chemical class 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
150000002314 glycerols Chemical class 0.000 claims description 2
150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 2
-1 polyoxyethylene Polymers 0.000 claims description 2
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
229920000136 polysorbate Polymers 0.000 claims description 2
239000002563 ionic surfactant Substances 0.000 claims 1
230000001716 anti-fugal effect Effects 0.000 abstract 3
238000002663 nebulization Methods 0.000 abstract 2
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
239000010410 layer Substances 0.000 description 10
230000002776 aggregation Effects 0.000 description 6
238000005054 agglomeration Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000007921 spray Substances 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
239000000126 substance Substances 0.000 description 4
229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
229960004793 sucrose Drugs 0.000 description 3
229920002472 Starch Polymers 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011247 coating layer Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
238000007789 sealing Methods 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
150000003851 azoles Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
229960002737 fructose Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960001031 glucose Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
229940074410 trehalose Drugs 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

NO20010289A 1998-07-21 2001-01-17 Oral farmasoytisk sammensetning med en forbindelse som har antisopp aktivitet og en metode for dens fremstilling NO320054B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
ES009801539A ES2157731B1 (es)	1998-07-21	1998-07-21	Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
PCT/ES1999/000230 WO2000004881A1 (es)	1998-07-21	1999-07-20	Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion

Publications (3)

Publication Number	Publication Date
NO20010289D0 NO20010289D0 (no)	2001-01-17
NO20010289L NO20010289L (no)	2001-03-07
NO320054B1 true NO320054B1 (no)	2005-10-17

Family

ID=8304581

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20010289A NO320054B1 (no)	1998-07-21	2001-01-17	Oral farmasoytisk sammensetning med en forbindelse som har antisopp aktivitet og en metode for dens fremstilling

Country Status (30)

Country	Link
US (1)	US6737082B1 (de)
EP (1)	EP1103252B1 (de)
JP (1)	JP4190732B2 (de)
KR (1)	KR100572135B1 (de)
AT (1)	ATE234077T1 (de)
AU (1)	AU750730B2 (de)
BG (1)	BG65187B1 (de)
BR (1)	BR9912300A (de)
CA (1)	CA2337509C (de)
CZ (1)	CZ291938B6 (de)
DE (1)	DE69905905T2 (de)
DK (1)	DK1103252T3 (de)
EE (1)	EE04415B1 (de)
ES (2)	ES2157731B1 (de)
HR (1)	HRP20010128B1 (de)
HU (1)	HU228895B1 (de)
IL (1)	IL140910A (de)
ME (1)	MEP26708A (de)
MX (1)	MXPA01000681A (de)
NO (1)	NO320054B1 (de)
NZ (1)	NZ509886A (de)
PL (1)	PL194740B1 (de)
PT (1)	PT1103252E (de)
RS (1)	RS50063B (de)
RU (1)	RU2209628C2 (de)
SK (1)	SK283279B6 (de)
TR (1)	TR200100177T2 (de)
UA (1)	UA64009C2 (de)
WO (1)	WO2000004881A1 (de)
ZA (1)	ZA200101293B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1122456C (zh) *	1996-01-31	2003-10-01	南亚拉巴马医学科学基金会	含有天然的还原叶酸盐异构体的食品和维生素制品
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GEP20053427B (en)	1999-12-23	2005-01-25	Pfizer Prod Inc	Pharmaceutical Compositions Providing Enhanced Drug Concentrations
FR2842736B1 (fr)	2002-07-26	2005-07-22	Flamel Tech Sa	Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040115287A1 (en) *	2002-12-17	2004-06-17	Lipocine, Inc.	Hydrophobic active agent compositions and methods
DK1438961T4 (da) *	2003-01-14	2014-11-17	Acino Pharma Ag	Bioækvivalent sammensætning af itraconazol dispergeret i en hydrofil polymer
EP1438960B2 (de) *	2003-01-14	2012-12-19	Acino Pharma AG	Zusammensetzung in Form eines festen Dispersion enthaltend Itraconazol und ein hydrophilisches Polymer mit einer verbesserten Bioverfügbarkeit
FR2852607B1 (fr) *	2003-03-20	2006-07-14		Procede de fabrication de microspheres de sucre de petite taille, les microspheres susceptibles d'etre obtenues par ce procede et leurs applications
FR2857591B1 (fr) *	2003-07-17	2007-11-02	Ethypharm Sa	Particules comprenant un principe actif sous forme de co-precipite
WO2005011702A1 (en) *	2003-07-17	2005-02-10	Tibotec Pharmaceuticals Ltd.	Process for preparing particles containing an antiviral
FR2883179B1 (fr)	2005-03-18	2009-04-17	Ethypharm Sa	Comprime enrobe
US8653083B2 (en)	2005-08-22	2014-02-18	The Johns Hopkins University	Hedgehog pathway antagonists to treat disease
CN101283984B (zh) *	2007-04-12	2010-05-26	永胜药品工业股份有限公司	高生物使用率的经杀真菌剂和聚合物涂覆的核心微粒状物
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
JP2013521249A (ja) *	2010-03-05	2013-06-10	ビーエーエスエフソシエタス・ヨーロピア	融解物で被覆された医薬形態
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
MA40982A (fr) *	2014-11-19	2017-09-26	Biogen Ma Inc	Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
JP2018520114A (ja) *	2015-05-25	2018-07-26	サンファーマシューティカルインダストリーズリミテッドＳｕｎＰｈａｒｍａｃｅｕｔｉｃａｌＩｎｄｕｓｔｒｉｅｓＬｔｄ．	イソトレチノインの１日１回経口医薬組成物
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
CA3033065A1 (en)	2016-08-11	2018-02-15	Adamis Pharmaceuticals Corporation	Drug compositions
US11559530B2 (en)	2016-11-28	2023-01-24	Lipocine Inc.	Oral testosterone undecanoate therapy
US11564910B2 (en)	2017-12-08	2023-01-31	Adamis Pharmaceuticals Corporation	Drug compositions
EP3786231A4 (de) *	2018-04-27	2021-06-09	Toppan Printing Co., Ltd.	Kompositteilchen mit verzögerter freisetzung, verfahren zur herstellung von kompositpartikeln mit verzögerter freisetzung, trockenpulver und tapete
AU2019308326B2 (en)	2018-07-20	2025-07-31	Lipocine Inc.	Liver disease
EP4452232A1 (de) *	2021-12-22	2024-10-30	Palau Pharma, S.L.U.	Multipartikuläre albaconazolzusammensetzung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4267179A (en) *	1978-06-23	1981-05-12	Janssen Pharmaceutica, N.V.	Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4916134A (en) *	1987-03-25	1990-04-10	Janssen Pharmacuetica N.V.	4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IE61651B1 (en) *	1990-07-04	1994-11-16	Zambon Spa	Programmed release oral solid pharmaceutical dosage form
PH30929A (en) *	1992-09-03	1997-12-23	Janssen Pharmaceutica Nv	Beads having a core coated with an antifungal and a polymer.
PH31594A (en) *	1993-09-30	1998-11-03	Janssen Pharmaceutica Nv	Oral formulations on an antifungal.
US5567441A (en) *	1995-03-24	1996-10-22	Andrx Pharmaceuticals Inc.	Diltiazem controlled release formulation
ATE255883T1 (de) *	1996-05-20	2003-12-15	Janssen Pharmaceutica Nv	Fungizide mittel mit verbesserter bioverfügbarkeit
CA2255663C (en) *	1996-05-24	2002-08-20	Schering Corporation	Antifungal composition with enhanced bioavailability
CA2258683C (en) *	1996-06-28	2007-07-31	Schering Corporation	Oral composition comprising a triazole antifungal compound
DE19626924C2 (de) *	1996-07-04	1999-08-19	Epazon B V	Gerät zur Bereitstellung eines Atemgases
JP3608800B2 (ja) *	1997-03-26	2005-01-12	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	抗真菌剤およびポリマーでコートされたコアを有するペレット剤

1998
- 1998-07-21 ES ES009801539A patent/ES2157731B1/es not_active Expired - Fee Related
1999
- 1999-07-20 SK SK86-2001A patent/SK283279B6/sk not_active IP Right Cessation
- 1999-07-20 EP EP99931261A patent/EP1103252B1/de not_active Expired - Lifetime
- 1999-07-20 CA CA002337509A patent/CA2337509C/en not_active Expired - Fee Related
- 1999-07-20 EE EEP200100041A patent/EE04415B1/xx not_active IP Right Cessation
- 1999-07-20 DK DK99931261T patent/DK1103252T3/da active
- 1999-07-20 PT PT99931261T patent/PT1103252E/pt unknown
- 1999-07-20 AU AU47821/99A patent/AU750730B2/en not_active Ceased
- 1999-07-20 IL IL14091099A patent/IL140910A/en not_active IP Right Cessation
- 1999-07-20 PL PL99345625A patent/PL194740B1/pl not_active IP Right Cessation
- 1999-07-20 US US09/744,322 patent/US6737082B1/en not_active Expired - Fee Related
- 1999-07-20 AT AT99931261T patent/ATE234077T1/de active
- 1999-07-20 WO PCT/ES1999/000230 patent/WO2000004881A1/es not_active Ceased
- 1999-07-20 NZ NZ509886A patent/NZ509886A/xx not_active IP Right Cessation
- 1999-07-20 RS YUP-39/01A patent/RS50063B/sr unknown
- 1999-07-20 RU RU2001104894/14A patent/RU2209628C2/ru not_active IP Right Cessation
- 1999-07-20 DE DE69905905T patent/DE69905905T2/de not_active Expired - Lifetime
- 1999-07-20 HR HR20010128A patent/HRP20010128B1/xx not_active IP Right Cessation
- 1999-07-20 HU HU0103708A patent/HU228895B1/hu not_active IP Right Cessation
- 1999-07-20 UA UA2001021260A patent/UA64009C2/uk unknown
- 1999-07-20 ME MEP-267/08A patent/MEP26708A/xx unknown
- 1999-07-20 BR BR9912300-2A patent/BR9912300A/pt not_active Application Discontinuation
- 1999-07-20 JP JP2000560874A patent/JP4190732B2/ja not_active Expired - Fee Related
- 1999-07-20 CZ CZ2001175A patent/CZ291938B6/cs not_active IP Right Cessation
- 1999-07-20 KR KR1020017000783A patent/KR100572135B1/ko not_active Expired - Fee Related
- 1999-07-20 MX MXPA01000681A patent/MXPA01000681A/es active IP Right Grant
- 1999-07-20 ES ES99931261T patent/ES2194480T3/es not_active Expired - Lifetime
- 1999-07-20 TR TR2001/00177T patent/TR200100177T2/xx unknown
2001
- 2001-01-17 NO NO20010289A patent/NO320054B1/no not_active IP Right Cessation
- 2001-02-15 ZA ZA200101293A patent/ZA200101293B/en unknown
- 2001-02-21 BG BG105282A patent/BG65187B1/bg unknown

Also Published As

Publication number	Publication date
AU750730B2 (en)	2002-07-25
BG105282A (en)	2001-11-30
ES2194480T3 (es)	2003-11-16
NZ509886A (en)	2002-09-27
SK862001A3 (en)	2001-08-06
KR20010070990A (ko)	2001-07-28
JP2002521323A (ja)	2002-07-16
TR200100177T2 (tr)	2001-07-23
ES2157731A1 (es)	2001-08-16
IL140910A (en)	2004-03-28
EE04415B1 (et)	2005-02-15
NO20010289D0 (no)	2001-01-17
HRP20010128B1 (en)	2003-12-31
MEP26708A (en)	2010-06-10
DE69905905T2 (de)	2004-03-04
KR100572135B1 (ko)	2006-04-19
JP4190732B2 (ja)	2008-12-03
RS50063B (sr)	2009-01-22
UA64009C2 (en)	2004-02-16
AU4782199A (en)	2000-02-14
CA2337509A1 (en)	2000-02-03
HRP20010128A2 (en)	2002-12-31
ES2157731B1 (es)	2002-05-01
DE69905905D1 (de)	2003-04-17
EP1103252A1 (de)	2001-05-30
ATE234077T1 (de)	2003-03-15
HUP0103708A2 (hu)	2002-02-28
HK1037531A1 (en)	2002-02-15
BG65187B1 (bg)	2007-06-29
PL345625A1 (en)	2002-01-02
NO20010289L (no)	2001-03-07
EE200100041A (et)	2002-06-17
YU3901A (sh)	2003-08-29
CZ291938B6 (cs)	2003-06-18
HUP0103708A3 (en)	2002-07-29
WO2000004881A1 (es)	2000-02-03
RU2209628C2 (ru)	2003-08-10
HU228895B1 (en)	2013-06-28
MXPA01000681A (es)	2002-04-24
EP1103252B1 (de)	2003-03-12
IL140910A0 (en)	2002-02-10
PT1103252E (pt)	2003-07-31
ZA200101293B (en)	2001-08-21
CZ2001175A3 (en)	2001-05-16
DK1103252T3 (da)	2003-07-14
PL194740B1 (pl)	2007-06-29
CA2337509C (en)	2005-12-27
BR9912300A (pt)	2001-04-17
SK283279B6 (sk)	2003-05-02
US6737082B1 (en)	2004-05-18

Legal Events

Date	Code	Title	Description
2015-02-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO320054B1 (no)	2005-10-17	Oral farmasoytisk sammensetning med en forbindelse som har antisopp aktivitet og en metode for dens fremstilling
JP2865869B2 (ja)	1999-03-08	抗真菌剤とポリマーを用いてコーティングされた核をもつビーズ
EP0630646B1 (de)	2002-07-31	Formulierungen mit kontrollierter Abgabe überzogen mit wässrigen Dispersionen von Ethylcellulose
EP1350508B1 (de)	2005-11-16	Fungizide Zubereitung und Methoden zu ihrer Herstellung und Verwendung
PL190566B1 (pl)	2005-12-30	Peletka, zawierająca rdzeń pokryty itrakonazolem i polimerem i sposób jej wytwarzania oraz postać dawki farmaceutycznej
HK1037531B (en)	2003-07-18	Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method
US20070148240A1 (en)	2007-06-28	Oral formulation containing itraconazole and methods for manufacturing and using the same
US7314641B1 (en)	2008-01-01	High-bioavailability particle coated with fungicide and polymer